GPR171
GPR171, also known as platelet activating factor H963, is a member of the class A rhodopsin family of heterotrimeric G-protein coupled receptors. Until 2013, GPR171 was an orphan receptor, it is now known to be activated by the endogenous proSAAS-derived peptide BigLEN.
GPR171 Agonists |
|
---|---|
Cat. No. | 产品名称/活性 |
6304 | BigLEN (mouse) |
GPR171 agonist | |
GPR171 Antagonists |
|
Cat. No. | 产品名称/活性 |
6298 | MS 21570 |
GPR171 antagonist |
GPR171, also known as platelet activating factor H963, is a member of the class A rhodopsin family of heterotrimeric G-protein coupled receptors. Until 2013, GPR171 was an orphan receptor, it is now known to be activated by the endogenous proSAAS-derived peptide BigLEN.
Expressed in the basolateral amygdala, and also in the hypothalamus where it co-localizes with its ligand, BigLEN, GPR171 shows high levels of similarity to P2Y receptors but exhibits different expression patterns and is not activated by carboxylic acids.
Activation of GPR171 has been shown to increase weight gain and food intake in mice, so the receptor is a target for research into obesity and eating disorders. GPR171 is also of interest to cancer researchers, as multiple gene copies are commonly present in cancer cells and are associated with their proliferation and migration. In addition, it has been shown that GPR171 expression inhibits myeloid differentiation in hematopoietic cell lines.
External sources of pharmacological information for GPR171 :
Literature for GPR171
Tocris offers the following scientific literature for GPR171 to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peptides Involved in Appetite Modulation Scientific Review
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.